The Medicines and Healthcare products Regulatory Agency (MHRA) published a pharmacovigilance update for 2021, when the transition period for Brexit ends. If there are no changes in the coming months, from January 2021 all pharmacovigilance activities for UK authorised products will have to be managed according to the indications on this link or by clicking on the image below.
